Macquarie 04-Feb-14
The US FDA is investigating the safety of TRT (testosterone replacement therapy), following studies suggesting a cardiovascular risk. Macquarie notes the discretionary nature of TRT means the impact, if the FDA concludes there's a risk, could be meaningful.
Adding other headwinds to the stock's valuation such as price declines, the tailing of rebates and the generic gels entering the market means Macquarie finds the stock expensive. The Underperform rating is retained and the price target is reduced to $1.80 from $2.24.
Underperform
Thats it - i'm out!!
- Forums
- ASX - By Stock
- ACR
- us fda is investigating the safety of trt
us fda is investigating the safety of trt
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.4¢ |
Change
0.001(1.59%) |
Mkt cap ! $18.31M |
Open | High | Low | Value | Volume |
6.3¢ | 6.4¢ | 6.3¢ | $12.84K | 200.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 102789 | 6.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.5¢ | 9537 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13144 | 0.063 |
1 | 200000 | 0.062 |
1 | 52500 | 0.061 |
8 | 498979 | 0.060 |
2 | 40000 | 0.059 |
Price($) | Vol. | No. |
---|---|---|
0.064 | 97211 | 2 |
0.065 | 9537 | 1 |
0.066 | 50000 | 1 |
0.067 | 100000 | 1 |
0.069 | 85000 | 1 |
Last trade - 13.52pm 30/08/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online